#United States #exosome therapy #Porton Advanced #Cranbury, NJ #UC-MSCs

Porton Advanced Achieves FDA Acceptance for UC-MSCs Cell Bank

In a significant achievement for Porton Advanced, the Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs) Cell Bank focused on exosome manufacturing has recently been accepted for filing by the U.S. FDA’s Center for Biologics Evaluation and Research (CBER) under Drug Master File (DMF) #32973. This acceptance not only marks a pivotal moment for Porton Advanced but also strengthens its position in the rapidly changing landscape of exosome therapeutics.

Enhancements in Regulatory Processes

With the FDA acceptance, sponsors embarking on exosome-related programs can now refer to DMF #32973 in their regulatory submissions. This development is set to boost the efficiency of U.S. FDA review pathways, thereby decreasing unnecessary duplication in documentation. The streamlined process will significantly enhance the execution of exosome-related therapies, which are hailed for their potential in various therapeutic applications.

Advanced Manufacturing Capabilities

Porton Advanced's exosome manufacturing platform is built on a foundation of Good Manufacturing Practice (GMP)-compliance, acknowledging the importance of quality in the production of biotherapeutics. The organization has developed an exhaustive set of manufacturing and quality control systems that guarantee the purity, activity, and stability of exosome products. Key features of their manufacturing approach include:

• - Flexible Cell Culture Systems: These systems support multiple cell lines including HEK293, MSC, K562, and iPSC, providing sponsors with the flexibility to choose the most suitable cell source for their specific therapeutic needs.
• - Scalable and Robust Processes: The platform allows for scalability from 2L to 50L bioreactors, ensuring a smooth transition from research and development to commercial production.
• - High Yield Production: Porton Advanced guarantees a final concentration of exosome products of at least 1E+11 particles/mL, emphasizing their commitment to high-quality outputs.
• - Rapid Delivery: Clients can expect GMP-grade exosomes within just one month, significantly accelerating the time frame to get these products into clinical settings.
• - Stringent QC Testing: A comprehensive approach to quality control involves rigorous testing for identity, purity, potency, and safety, ensuring batch-to-batch consistency.

Commitment to Future Innovations

Looking ahead, Porton Advanced aims to further exploit the potential of exosome technology within drug development and broader regenerative medicine. They are committed to providing comprehensive integrated exosome services, from customization of raw materials to final formulation development. This holistic approach is designed to support global partners by enhancing their operational efficiencies in bringing new therapies to patients.

About Porton Advanced

Porton Advanced Solutions is a well-regarded subsidiary of Porton Pharma Solutions, a leading contract development and manufacturing organization (CDMO). With dual headquarters located in Cranbury, New Jersey, and Suzhou, China, Porton Advanced facilitates end-to-end CDMO solutions across Advanced Therapy Medicinal Products (ATMPs). Their offerings include plasmids, viral vectors, cell therapies, and nucleic acid therapies, covering all stages of drug development from early research and Investigational New Drug (IND) applications to clinical trials and commercialization. The company boasts state-of-the-art GMP-compliant facilities that encompass an astonishing 215,000 square feet, housing multiple production capacities including 10 viral vector production lines and several dedicated cell therapy production suites.

In conclusion, the acceptance of Porton Advanced's UC-MSCs Cell Bank by the FDA spells a transformative change for the company and illustrates its potential to reshape the exosome manufacturing landscape. This development not only paves the way for accelerated treatments but also signifies a step forward in the quest for innovative therapies in regenerative medicine.